NIPPON KAYAKU CO.,LTD. [4272.T]
TOKYO, Mar 30 (Pulse News Wire) – Nippon Kayaku CO.,LTD. (4272.T) announced today that its board of directors approved the acquisition of shares in a newly established subsidiary of Fuji Yakuhin Co., Ltd.
The subsidiary will inherit part of Fuji Yakuhin’s pharmaceutical manufacturing operations, specifically focusing on contract development and production of injectable medical drugs at the Toyama Second Plant. Under the agreement, Fuji Yakuhin will establish a new subsidiary and transfer the targeted business through absorption division. NIPPON KAYAKU plans to acquire all outstanding shares of the new subsidiary. The transaction aims to strengthen supply stability and expand production capacity for anticancer drugs and biosimilars, key components of its pharmaceutical business. Expected sales revenue for the inherited business is approximately ¥3 billion for the fiscal year ending March 2026. Capital of the new subsidiary will be set at ¥1 million.
The new entity is scheduled to be established on April 30, 2026. Key milestones for the transaction include the establishment of the new subsidiary on April 30, 2026, effectiveness of the absorption division on October 01, 2026, and completion of share transfers on October 1, 2026. However, schedules may be adjusted based on regulatory approvals and other circumstances. Fuji Yakuhin, headquartered in Saitama Prefecture, was founded on April 27, 1954, with a capital of ¥100 million. As of March 31, 2025, its net assets stood at ¥38.12 billion and total assets at ¥116.7 billion. In the long term, NIPPON KAYAKU expects this move to enhance its operational performance and corporate value.
The impact on the consolidated results for the fiscal year ending March 2026 is expected to be minor.
🟢 Confidence: High AI-translated content.